Financial Results
Nutraplus India Approves Unaudited H1 FY27 Results
Nutraplus India approved unaudited standalone financial results for the quarter and half year ended 30 September 2026, along with the limited review report.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q4 FY26
Investor Presentation
Q4 FY26
Investor Presentation
Q4 FY26
Financial Results
Nutraplus India approved unaudited standalone financial results for the quarter and half year ended 30 September 2026, along with the limited review report.
Board Meeting
Nutraplus India postponed its Board meeting from 12 November to 14 November 2026 at 3:00 p.m. due to the pending Chartered Accountant’s LRR report.
this company is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
this company operates in the its sector sector. Review the About Company section on this page to understand its business model, revenue streams, and key products or services.
Over the past 52 weeks, this company has traded between a low of ₹0.00 and a high of ₹0.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
this company has a market capitalization of approximately N/A. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
this company’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of N/A and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of N/A Cr, this company is classified as a N/A stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
this company operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of this company is N/A. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Nutraplus said it lost all property, plant and equipment under the Act cited in its filing as the SARFESIA Act, 2002. The company said it became a non-performing asset in financial year 2019-20 and that the bank auction eventually succeeded after a COVID-19-related delay.
Nutraplus India Limited adjourned the meeting from 12 November to 14 November 2026 because of a delayed CA report, according to the BSE notice. The supplied disclosure does not provide further details about the report delay.
FY25 net loss was ₹0.0501 crore, versus ₹0.0616 crore in FY24, showing a slight year-on-year reduction in losses.
FY25 net loss was ₹0.05 crore versus ₹0.06 crore in FY24, a marginal improvement based on the disclosed figures.